New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
10:01 EDTABBV, VRTX, TRLA, DLA, MLNX, PFE, VCLK, OPTR, FIO, SYRG, RBCN, FLY, GOOGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Delta Apparel (DLA) initiated with a Buy at Roth Capital... Fly Leasing (FLY) initiated with a Buy at Deutsche Bank... Google (GOOG) initiated with a Neutral at Sterne Agee... Optimer (OPTR) initiated with an Outperform at RW Baird... Trulia (TRLA) initiated with a Neutral at Goldman... ValueClick (VCLK) initiated with a Buy at Goldman... Vertex (VRTX) initiated with an Outperform at RW Baird... Rubicon (RBCN) coverage resumed with an Underweight at Piper Jaffray... Synergy Resources (SYRG) initiated with a Buy at Canaccord... Pfizer (PFE) reinstated with a Neutral at Credit Suisse... AbbVie (ABBV) initiated with a Neutral at Credit Suisse... Fusion-io (FIO) initiated with a Neutral at Janney Capital... Mellanox (MLNX) initiated with a Buy at Janney Capital.
News For GOOG;DLA;FLY;OPTR;TRLA;RBCN;VCLK;VRTX;SYRG;PFE;ABBV;FIO;MLNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
May 19, 2015
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
06:59 EDTGOOGYouTube Kids app receives complaints of 'inappropriate content', WSJ says
Subscribe for More Information
06:55 EDTPFEGenocea could be takeover target after data, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff expects Genocea Biosciences (GNCA) will report positive Phase II GEN-003 post-immunization results late in Q2. GEN-003 is a therapeutic vaccine for genital herpes targeting Herpes Simplex Virus Type 2. Positive GEN-003 data could position Genocea as a potential acquisition target by a larger vaccine player, Tenthoff tells investors today in a research note. Large vaccine makers include Sanofi (SNY), Merck (MRK), GlaxoSmithKline (GSK), Pfizer (PFE) and Novartis (NVS). The analyst reiterates an Overweight rating on Genocea with a $14 price target. Shares of the clinical-stage vaccine developer with a $227M market capitalization closed yesterday up 83c to $10.22.
May 18, 2015
14:18 EDTMLNXMellanox says HPC is less than 50% of revenue
Subscribe for More Information
11:47 EDTGOOGAmazon unlikely hurt by Google Buy button in next 3 years, says Piper Jaffray
Piper Jaffray analyst Gene Munster said he does not expect Google's (GOOG) addition of a "Buy" button for mobile e-commerce hurting Amazon.com (AMZN) over the next 1 to 3 years, but he does believe Google's plan presents a longer-term threat to "chip away" at Amazon's growth rate. However, Munster thinks it will be "next to impossible" for Google to replicate Amazon's core infrastructure and customer experience and he keeps an Overweight rating and $475 price target on Amazon shares.
08:22 EDTGOOGVerizon deal has multiple positive catalysts, says Wells Fargo
Subscribe for More Information
07:59 EDTGOOGGoogle Buy button a natural fit for mobile shopping listings, says Baird
Baird noted Google added a Buy button to accompany mobile product listings and believes it will improve the company's e-commerce search competitiveness. Baird reiterated its Outperform rating and $690 price target on Google shares.
07:27 EDTMLNXJPMorgan to hold a conference
Subscribe for More Information
06:58 EDTPFEActavis CEO says chances of Pfizer offer are 'unlikely', Financial Times says
Actavis (ACT) CEO Brent Saunders said the chances of Pfizer (PFE) making an offer are "incredibly unlikely," reports the Financial Times. Saunders said he has heard the gossip that Actavis could become a takeover target for a larger group, but he spends "zero time thinking about it." Reference Link
May 17, 2015
18:56 EDTGOOGGoogle to feature 'buy' button in sponsored search results, WSJ says
Subscribe for More Information
16:50 EDTGOOGWhite House wavers on backing Google, Oracle in copyright suit, Reuters says
Subscribe for More Information
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
May 15, 2015
16:46 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
AbbVie (ABBV) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics (PCYC) to 5 p.m., New York City time, on May 22. The depositary of the exchange offer has advised that, as of 4:00 p.m., New York City time, on May 15, a total of approximately 42,822,941 shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer. All other terms and conditions of the exchange offer remain unchanged.
16:28 EDTGOOGAppaloosa Management gives quarterly update on stakes
Subscribe for More Information
10:29 EDTABBVAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:45 EDTABBVAbbVie reports FDA orphan designation for Humira in treatment of HS
Subscribe for More Information
09:31 EDTVRTX, PFEAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:46 EDTGOOGMobile operators ad blocking plan sets up fight with Google, FT reports
Subscribe for More Information
07:22 EDTGOOGGoogle's self-driving cars to roll out in California this summer, Re/code says
Subscribe for More Information
06:24 EDTGOOGGoogle Glass team may be focusing on multiple wearable products, BI reports
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use